Callan Jmb INC 8-K filings

Callan JMB Inc. received a notice from Nasdaq for failing to meet the minimum bid price requirement, with 180 days to regain compliance.

Callan JMB Inc. announced the resignation of Executive Vice President Eric Kash, detailing a severance package and outstanding stock options.

Callan JMB Inc. received a deficiency letter from Nasdaq for failing to meet the minimum stockholders equity requirement, with a plan to regain compliance due by May 22, 2026.

Callan JMB Inc. announced its full year 2025 financial results, reporting a decrease in revenue and a significant increase in operating loss, while highlighting strategic growth initiatives in healthcare and emergency preparedness.

Callan JMB Inc. has amended its common stock purchase agreement with Hexstone Capital, LLC, extending the maturity date and revising key terms for future equity sales.

Callan JMB Inc. announced it will commence a series of investor presentations at the DealFlow Discovery Conference starting January 28, 2026.

Callan JMB Inc. shareholders re-elected five directors and ratified Rosenberg Rich Baker Berman, P.A. as the independent auditor for fiscal year 2025 at their annual meeting.

Callan JMB Inc. has updated its insider trading policy, adjusting the quarterly blackout period for company personnel.

Callan JMB Inc. has appointed Christopher Shields, previously Senior Vice President of Governmental Affairs, as its Interim Chief Financial Officer and Treasurer, effective December 1, 2025.

Callan JMB reports increased losses in Q3 2025 despite strategic expansions into food sampling and international markets, alongside key contract extensions.

Callan JMB Inc. announced its second quarter 2025 financial results, reporting a net loss of $1.4 million on decreased revenue, while highlighting strategic partnerships and international expansion.

Callan JMB Inc. has entered into a new purchase agreement providing access to up to $25 million in equity financing, offering flexible capital for general corporate purposes.

Callan JMB reports Q1 2025 financial results, including revenue of $1.45 million and a net loss of $1.2 million, while also providing a business update highlighting growth initiatives and contract renewals.

Callan JMB Inc. successfully closed its initial public offering and the underwriter partially exercised its over-allotment option, resulting in gross proceeds of $5.77 million.